didn't they indicate >40% growth in their 4C (in April....the pro-forma number there for 9mths to Mar2021 was +44.6%)
I'm not sure what is new news here apart from them moving from 6% of phamacies being digital to 17% .....easier/cheaper to access patients for the pharma companies they are trying to attract?!?
No mention of outlook or on track for earlier guidance.....leaves them exposed to disappointing the market when you say 40% up YoY, but still bleeding cash....they need someone to reign in random stats and have clear, measurable targets that they communicate to the market rather than an account manager saying 1 client is spending more.
Add to My Watchlist
What is My Watchlist?
